A Phase II, Single Arm, Open Label Study of Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib - Study Drug AMN107

  • Markowitz, Avi, (PI)

    Project: Other project

    StatusFinished
    Effective start/end date6/1/136/30/19

    Funding

    • Novartis Pharmaceuticals Corporation: $23,407.00